Skip to main content

Market Overview

UPDATE: Wedbush Initiates Coverage On Tetraphase Pharmaceuticals On Room To Grow

Share:

In a report published Tuesday, Wedbush analyst Heather Behanna initiated coverage on Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) with an Outperform rating and $31.00 price target.

In the report, Wedbush noted, “Tetraphase Pharmaceuticals is a Lexington, MA-based biotechnology company focused on the development of antibiotics to combat multi-drug resistant infections. Its proprietary tetracycline chemistry platform has enabled a pipeline of differentiated clinical candidates. Lead compound eravacycline is in Phase III development for abdominal infections (cIAI) and urinary tract infections (cUTI). Eravacycline is a next-generation tetracycline available once or twice daily by infusion or in a tablet form – a key differentiator, in our view. We believe previous data for eravacycline has de-risked the pivotal studies; we anticipate positive data from the Phase III studies in cIAI and cUTI in 1Q15 and mid-2015, respectively, which we believe should act as catalysts for the stock. The stock has appreciated recently; however, we see room for further upside as Phase III data reads out next year, an ex-US partnership is struck, or the company is acquired.”

Tetraphase Pharmaceuticals closed on Tuesday at $23.49.

Latest Ratings for TTPH

DateFirmActionFromTo
Mar 2020Gabelli & Co.DowngradesHoldSell
Jan 2020Gabelli & Co.DowngradesBuyHold
Oct 2019Gabelli & Co.UpgradesHoldBuy

View More Analyst Ratings for TTPH

View the Latest Analyst Ratings

 

Related Articles (TTPH)

View Comments and Join the Discussion!

Posted-In: Heather Behanna WedbushAnalyst Color Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com